S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

SMMT Summit Therapeutics Inc

4.70

0.00 (0.00%)

Pre Market

Last Updated: 07:48:06

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Summit Therapeutics Charts.

Summit Therapeutics Plc News

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
Wednesday 1 May 2024 (1 day ago) • Business Wire

Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Wednesday 24 April 2024 (1 week ago) • Business Wire

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
Thursday 11 April 2024 (3 weeks ago) • Business Wire

Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
Wednesday 10 April 2024 (3 weeks ago) • Business Wire

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
Friday 22 March 2024 (1 month ago) • Business Wire

Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
Thursday 14 March 2024 (2 months ago) • Business Wire

Form 8-K - Current report
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Tuesday 5 March 2024 (2 months ago) • Business Wire

Form 8-K - Current report
Tuesday 20 February 2024 (2 months ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Tuesday 20 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 20 February 2024 (2 months ago) • Edgar (US Regulatory)

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
Tuesday 20 February 2024 (2 months ago) • Business Wire

More Summit Therapeutics Plc News Articles

Global Developments (PK)

Atacama Resources (PK)

FBEC Worldwide (PK)

NaturalShrimp (QB)

Mullen Automotive

NioCorp Developments

Verb Technology

Federal Home Loan Mortgage (QB)

Branded Legacy (PK)

Moon Equity (PK)

MicroCloud Hologram

International Star (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions